English
ХРОНИЧЕСКАЯ ОБСТРУКТИВНАЯ БОЛЕЗНЬ ЛЕГКИХ: ПОРЯДОК ДИАГНОСТИКИ И ФАРМАКОТЕРАПИЯ СТАБИЛЬНОГО ТЕЧЕНИЯ ЗАБОЛЕВАНИЯ
DOI: https://dx.doi.org/10.18565/therapy.2024.4suppl.102-119
Базовая структура инфографики соответствует следующим источникам:
Клинические рекомендации. Хроническая обструктивная болезнь легких. Российское респираторное общество. 2021. ID: 603. Доступ: https://cr.minzdrav.gov.ru/schema/603_2 (рубрикатор клинических рекомендаций Минздрава России).
Global strategy for prevention, diagnosis and management of COPD (GOLD): 2024 Report. URL: https://goldcopd.org/2024-gold-report/ (официальный сайт GOLD)
Клинические рекомендации (проект). Хроническая обструктивная болезнь легких. Российское респираторное общество, Российская общественная организация «Российское научное медицинское общество терапевтов». 2023. Доступ: https://spulmo.ru/upload/kr/HOBL_2023_draft.pdf (официальный сайт Российского респираторного общества)
Адаптировано и переработано со ссылками на использованную литературу
Литература
1. Клинические рекомендации. Хроническая обструктивная болезнь легких. Российское респираторное общество. Рубрикатор клинических рекомендаций Минздрава России. 2021. ID: 603. Доступ: https://cr.minzdrav.gov.ru/schema/603_2 (дата обращения – 01.03.2024). 2. Global strategy for prevention, diagnosis and management of COPD (GOLD): 2024 Report. URL: https://goldcopd.org/2024-gold-report/ (date of access – 01.03.2024). 3. Клинические рекомендации (проект). Хроническая обструктивная болезнь легких. Российское респираторное общество, Российская общественная организация «Российское научное медицинское общество терапевтов». 2023. Доступ: https://spulmo.ru/upload/kr/HOBL_2023_ draft.pdf (дата обращения – 01.03.2024). 4. Milacic N., Milacic B., Dunjic O. et al. Validity of CAT and mMRC – dyspnea score in evaluation of COPD severity. Acta Medica Medianae. 2015; 54(1): 66–70. https://doi.org/10.5633/amm.2015.0111. 5. Gruffydd-Jones K., Marsden H.C., Holmes S. et al. Utility of COPD Assessment Test (CAT) in primary care consultations: A randomised controlled trial. Prim Care Respir J. 2013; 22(1): 37–43. https://doi.org/10.4104/pcrj.2013.00001. PMID: 23282858. PMCID: PMC6442750. 6. Sestini P., Renzoni E., Robinson S. et al. Short-acting beta2-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002; (4): CD001495. https://doi.org/10.1002/14651858.CD001495. PMID: 12519559. 7. Vogelmeier C, Hederer B, Glaab T. et al.; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011; 364(12): 1093–103. https://doi.org/10.1056/NEJMoa1008378. PMID: 21428765. 8. Decramer M.L., Chapman K.R., Dahl R. et al.; INVIGORATE investigators. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): A randomised, blinded, parallel-group study. Lancet Respir Med. 2013; 1(7): 524–33. https://doi.org/10.1016/S2213-2600(13)70158-9. PMID: 24461613. 9. Wedzicha J.A., Banerji D., Chapman K.R. et al.; FLAME Investigators; Indacaterol – glycopyrronium versus salmeterol – fluticasone for COPD. N Engl J Med. 2016; 374(23): 2222–34. https://doi.org/10.1056/NEJMoa1516385. PMID: 27181606. 10. Calverley P.M.A., Anzueto A.R., Carter K. et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): A double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018; 6(5):337–44. https://doi.org/10.1016/S2213-2600(18)30102-4. PMID: 29605624. 11. Tashkin D.P., Celli B., Senn S. et al.; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15): 1543–54. https://doi.org/10.1056/NEJMoa0805800. PMID: 18836213. 12. Jones P.W., Rennard S.I., Agusti A. et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res. 2011; 12(1): 55. https://doi.org/10.1186/1465-9921-12-55. PMID: 21518460. PMCID: PMC3098801. 13. Ulrik C.S. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: A systematic review of clinical benefit. Int J Chron Obstruct Pulmon Dis. 2012; 7: 673–78. https://doi.org/10.2147/COPD.S35990. PMID: 23055716. PMCID: PMC3461699. 14. Sims M.W., Panettieri R.A. Jr. Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011; 6: 457–66. https://doi.org/10.2147/COPD.S15524. PMID: 22003291. PMCID: PMC3186744. 15. Decramer M.L., Hanania N.A., Lotvall J.O., Yawn B.P. The safety of long-acting b2-agonists in the treatment of stable chronic obstructive disease. Int J Chron Obstruct Pulmon Dis. 2013; 8: 53–64. https://doi.org/10.2147/COPD.S39018. PMID: 23378756. PMCID: PMC3558319. 16. Kew K.M., Mavergames C., Walters J.A.E. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013; (10): CD010177. https://doi.org/10.1002/14651858.CD010177.pub2. PMID: 24127118. 17. Appleton S., Jones T., Poole P. et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006; 2006(3): CD006101. https://doi.org/10.1002/14651858.CD006101. PMID: 16856113. PMCID: PMC7200053. 18. Vincken W., Aumann J., Chen H. et al. Efficacy and safety of coadministration of oncedaily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: The GLOW6 study. Int J Chron Obstruct Pulmon Dis. 2014; 9: 215–28. https://doi.org/10.2147/COPD.S51592. PMID: 24596459. PMCID: PMC3940646. 19. Wedzicha J.A., Dahl R., Buhl R. et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med. 2014; 108(10): 1498–507. https://doi.org/10.1016/j.rmed.2014.07.011. PMID: 25135743. 20. Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015; 45(4): 969–79. https://doi.org/10.1183/09031936.00136014. PMID: 25573406. PMCID: PMC4391658. 21. Singh D., Jones P.W., Bateman E.D. et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): A multicentre, randomised study. BMC Pulm Med. 2014; 14: 178. https://doi.org/10.1186/1471-2466-14-178. PMID: 25404569. PMCID: PMC4273456. 22. Singh D., Agusti A., Martinez F.J. et al. Blood eosinophils and chronic obstructive pulmonary disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 review. Am J Respir Crit Care Med. 2022; 206(1); 17–24. https://doi.org/10.1164/rccm.202201-0209PP. PMID: 35737975. 23. Ferguson G.T., Rabe K.F., Martinez F.J. et al. Triple therapy with budesonide/glycopyrrolate/ formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): A double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Resp Med. 2018; 6(10): 747–58. https://doi.org/10.1016/S2213-2600(18)30327-8. PMID: 30232048. 24. Singh D. Papi A., Corradi M. et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double-blind, parallel group, randomised controlled trial. Lancet. 2016; 388(10048): 963–73. https://doi.org/10.1016/S0140-6736(16)31354-X. PMID: 27598678.
